Skip to main content

Table 2 Sensitivity of five screening questions together with their composite for epilepsy

From: High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20 years of community directed treatment with ivermectin

Question

Number with positive response (%)

Number confirmed with epilepsy (%)

Sensitivity (95% CI)

Q1a. Lost consciousness and experienced loss of bladder control

75 (30.7)

51

68.0 (54.2–78.8)

Q1b. Lost consciousness and experienced foaming in the mouth

61 (25.0)

49

80.3 (70.1–90.6)

Q2. Experienced absence or sudden loss of contact with the surroundings for a short duration of time

152 (61.9)

103

67.8 (60.2–75.3)

Q3. Experienced sudden, uncontrollable twitching or shaking of arms, legs or head for few minutes

119 (48.8)

69

58.0 (49.0–67.0)

Q4. Experienced sudden and brief bodily sensations, seen or heard things that were not there, or smelt strange odours

76 (31.15)

36

47.4 (35.9–58.9)

Q5. Ever been diagnosed with epilepsy

110 (44.26)

95

86.4 (79.8–92.9)